Related Experiment Video
Updated: Apr 23, 2026
Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions
Published on: January 20, 2022
Study of galectins in tumor immunity: strategies and methods
Juan P Cerliani1, Tomas Dalotto-Moreno, Daniel Compagno
1Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), C1428, Buenos Aires, Argentina, jpcerliani@gmail.com.
Abstract:
During the past decade, a better understanding of the cellular and molecular mechanisms underlying tumor immunity has provided the appropriate framework for the development of therapeutic strategies for cancer immunotherapy. Under this complex scenario, galectins have emerged as promising molecular targets for cancer therapy responsible of creating immunosuppressive microenvironments at sites of tumor growth and metastasis. Galectins, expressed in tumor, stromal, and endothelial cells, contribute to thwart the development of immune responses by favoring the expansion of T regulatory cells and contributing to their immunosuppressive activity, driving the differentiation of tolerogenic dendritic cells, limiting T cell viability, and maintaining T cell anergy. The emerging data promise a future scenario in which the selective blockade of individual members of the galectin family, either alone or in combination with other therapeutic regimens, will contribute to halt tumor progression by counteracting tumor-immune escape. Here we describe a selection of methods used to investigate the role of galectin-1 in tumor-immune escape.
Insights
Galectins create immunosuppressive tumor microenvironments, hindering anti-cancer immunity. Targeting galectins, like galectin-1, offers a promising strategy to enhance cancer immunotherapy by counteracting tumor immune escape.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Advances in understanding tumor immunity have paved the way for cancer immunotherapy.
- Galectins are implicated in creating immunosuppressive tumor microenvironments, promoting tumor growth and metastasis.
- Galectins contribute to immune evasion by modulating T cells and dendritic cells.
Purpose of the Study:
- To investigate the role of galectins as molecular targets in cancer therapy.
- To explore how galectins contribute to tumor-immune escape.
- To describe methods for studying galectin-1's function in tumor immunity.
Main Methods:
- Review and description of experimental methods.
- Focus on techniques to investigate galectin-1's role in tumor-immune escape.
- Analysis of galectin expression in tumor, stromal, and endothelial cells.
Main Results:
- Galectins promote immune suppression by expanding regulatory T cells and inducing tolerogenic dendritic cells.
- Galectins limit T cell viability and maintain T cell anergy, contributing to immune evasion.
- Galectin-1 is a key player in facilitating tumor immune escape.
Conclusions:
- Selective blockade of galectins presents a promising therapeutic strategy for cancer treatment.
- Targeting galectins can counteract tumor immune escape and halt tumor progression.
- Combination therapies involving galectin blockade may enhance overall therapeutic efficacy in cancer immunotherapy.
More Related Videos
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
10:59Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025
Related Concept Videos
01:25Selectins
01:27Tumor Immunotherapy